• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过替代标志物量化间接治疗效果。

Quantifying the indirect treatment effect via surrogate markers.

作者信息

Qu Yongming, Case Michael

机构信息

Eli Lilly and Company, Indianapolis, IN 46285, USA.

出版信息

Stat Med. 2006 Jan 30;25(2):223-31. doi: 10.1002/sim.2176.

DOI:10.1002/sim.2176
PMID:16143992
Abstract

As to the proportion of treatment effect (PTE) explained by surrogate markers, existing research has been focused on how to decompose the treatment effect into two parts: the treatment effect via surrogate markers and the treatment effect not explained by surrogate markers. Most proposed methods quantify the PTE explained by a single surrogate marker, or quantify the PTE explained by multiple surrogate markers without considering the cause-effect relationship among surrogate markers. The change of one marker may sometimes be due to changes in other markers. In this case, quantifying the association between multiple treatment effects via surrogates may also be important. In this paper, a method to quantify the possible causal relationship between surrogate markers is proposed. The new method can also be related to path analysis, a widely used analysis in sociology. Therefore, the proposed method can be viewed as a generalization of path analysis to generalized linear models and Cox regression models.

摘要

关于替代标志物所解释的治疗效果比例(PTE),现有研究主要集中于如何将治疗效果分解为两部分:通过替代标志物的治疗效果以及未被替代标志物解释的治疗效果。大多数提出的方法量化单个替代标志物所解释的PTE,或者量化多个替代标志物所解释的PTE,而不考虑替代标志物之间的因果关系。一个标志物的变化有时可能是由于其他标志物的变化。在这种情况下,量化通过替代物的多种治疗效果之间的关联可能也很重要。本文提出了一种量化替代标志物之间可能因果关系的方法。新方法还可以与路径分析相关联,路径分析是社会学中广泛使用的一种分析方法。因此,所提出的方法可以被视为路径分析对广义线性模型和Cox回归模型的推广。

相似文献

1
Quantifying the indirect treatment effect via surrogate markers.通过替代标志物量化间接治疗效果。
Stat Med. 2006 Jan 30;25(2):223-31. doi: 10.1002/sim.2176.
2
Quantifying the treatment effect explained by markers in the presence of measurement error.在存在测量误差的情况下,对由标志物解释的治疗效果进行量化。
Stat Med. 2007 Apr 30;26(9):1955-63. doi: 10.1002/sim.2695.
3
Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?替代终点的统计学验证:骨密度是骨折的有效替代指标吗?
J Musculoskelet Neuronal Interact. 2004 Mar;4(1):64-74.
4
Adjustment for the measurement error in evaluating biomarkers.调整评估生物标志物的测量误差。
Stat Med. 2010 Sep 30;29(22):2338-46. doi: 10.1002/sim.3993.
5
[Biochemical markers of bone remodeling: recent data of their applications in managing postmenopausal osteoporosis].[骨重塑的生化标志物:其在绝经后骨质疏松症管理中应用的最新数据]
Tunis Med. 2006 Nov;84(11):751-7.
6
The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.雷洛昔芬对居住在长期护理机构中的老年女性骨转换标志物的影响。
J Am Geriatr Soc. 2004 May;52(5):779-83. doi: 10.1111/j.1532-5415.2004.52218.x.
7
Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.雷洛昔芬治疗对骨代谢标志物PINP的降低作用及其与椎体骨折风险的关系。
Bone. 2004 Feb;34(2):344-51. doi: 10.1016/j.bone.2003.10.004.
8
[Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].[选择性雌激素受体调节剂对骨骼健康的影响。使用骨转换标志物评估雷洛昔芬治疗老年骨质疏松症女性的疗效]
Clin Calcium. 2010 Mar;20(3):413-20.
9
Mistake on quantifying the indirect treatment effect via surrogate markers by Y. Qu and M. Case Statistics in Medicine 2006; 25:223-231.
Stat Med. 2010 Aug 30;29(19):2067; author reply 2068. doi: 10.1002/sim.3932.
10
Biomarkers of bone health and osteoporosis risk.骨骼健康和骨质疏松症风险的生物标志物。
Proc Nutr Soc. 2008 May;67(2):157-62. doi: 10.1017/S002966510800699X.

引用本文的文献

1
Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.知情决策:代理评估的统计方法及其在许可和报销评估中的作用。
Pharm Stat. 2022 Jul;21(4):740-756. doi: 10.1002/pst.2219.
2
Use of the likelihood reduction factor in a path analysis framework to quantify surrogacy in clinical trials.在路径分析框架中使用似然减少因子来量化临床试验中的替代指标。
Stat Med. 2021 Dec 10;40(28):6373-6386. doi: 10.1002/sim.9188. Epub 2021 Sep 21.
3
Measuring Surrogacy in Clinical Research: With an application to studying surrogate markers for HIV Treatment-as-Prevention.
临床研究中的代孕测量:应用于研究艾滋病治疗即预防的替代指标
Stat Biosci. 2020 Dec;12(3):295-323. doi: 10.1007/s12561-019-09244-4. Epub 2019 Jun 4.
4
Relations of self-regulation and self-efficacy for exercise and eating and BMI change: A field investigation.锻炼和饮食的自我调节和自我效能感与 BMI 变化的关系:一项现场调查。
Biopsychosoc Med. 2010 Sep 3;4:10. doi: 10.1186/1751-0759-4-10.